| Literature DB >> 31450375 |
Tse-Wei Chen1, Umamaheswari Rajaji2, Shen-Ming Chen3, Bih-Show Lou4, Nabil Al-Zaqri5, Ali Alsalme6, Fahad A Alharthi6, Shih-Yi Lee7, Wen-Han Chang8.
Abstract
We have developed a graphitic carbon nitride covered vanadium oxide nanocomposite (V2O5@g-C3N4) by a simple sonochemical approach (50 kHz and 150 W/cm2). Furthermore, the morphology and chemical composition of the V2O5@g-C3N4 nanocomposite was carried out by X-rays diffractometry (XRD), transmission electron microscopy (TEM) and electrochemical impedance spectroscopy (EIS). Furthermore, the V2O5@g-C3N4 nanocomposite modified electrode was investigate electrochemical behavior of the anticancer drug. Compared with bare SPCE, V2O5/SPCE and g-C3N4/SPCE, V2O5@g-C3N4 modified SPCE showed highest current response towards anti-cancer drug (methotrexate). Furthermore, the modified sensor exhibits with a sharp peaks and wide linear range (0.025-273.15 μM) by using DPV with the sensitivity of 7.122 μA μM-1 cm-2. Notably, we have achieved a nanomolar detection limit (13.26 nM) for the DPV detection of methotrexate. Further, the practicability of the V2O5@g-C3N4 nanocomposite modified sensor can be used for real time sensing of methotrexate in drug and blood serum samples with good recover ranges. It has potential applications in routine analysis with high specificity, excellent reproducibility and good stability.Entities:
Keywords: Anti-cancer drug; Clinical analysis; Metal oxides; Nanocomposites; Sonochemical method; Voltammetric detection
Year: 2019 PMID: 31450375 DOI: 10.1016/j.ultsonch.2019.104664
Source DB: PubMed Journal: Ultrason Sonochem ISSN: 1350-4177 Impact factor: 7.491